ecopipam

Ecopipam (UNII-0X748O646K) 是一种有效的、选择性、具有口服活性的多巴胺 D1 D5 受体拮抗剂，Ki 值分别为 1.2 nM 和 2.0 nM。Ecopipam 对 D2、D4、5-HT 和 α2a 受体 (Ki=0.98，5.52，0.08 和 0.73 μM) 显示出超过 40 倍的选择性。Ecopipam 可用于精神分裂症、可卡因成瘾和肥胖症的研究。

Ecopipam (SCH 39166) hydrobromide 是一种高效、选择性的口服多巴胺D1 D5受体拮抗剂，其对D1和D5受体的Ki值分别为1.2 nM和2.0 nM。相比之下，它对D2、D4、5-HT及α2a受体（Ki分别为0.98、5.52、0.08及0.73 μM）的选择性超过40倍。Ecopipam hydrobromide主要用于精神分裂症和肥胖症的研究应用。

Ecopipam (SCH 39166) hydrochloride is a highly potent, selective, and orally active antagonist of dopamine D1 D5 receptors. It exhibits impressive binding affinities, with Ki values of 1.2 nM and 2.0 nM for D1 and D5 receptors, respectively. Ecopipam hydrochloride demonstrates remarkable selectivity, displaying over 40-fold selectivity compared to D2, D4, 5-HT, and α2a receptors, with Ki values of 0.98 μM, 5.52 μM, 0.08 μM, and 0.73 μM, respectively. Its application extends to various areas of research, including schizophrenia, cocaine addiction, and obesity [1] [3].